9 citations
,
April 2020 in “Journal of Cosmetic Dermatology” This case report describes the first instance of eosinophilic folliculitis of the scalp occurring during nivolumab therapy, which responded partially to topical steroids and cream but did not require stopping the treatment.
November 2022 in “Journal of the Endocrine Society” This case study reports that immunotherapy with ipilimumab and nivolumab induced hypophysitis in a patient with renal cell carcinoma, emphasizing the need for careful monitoring of endocrine function in such treatments.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” In this retrospective study of patients with advanced Merkel cell carcinoma responding to immunotherapy, those treated for 18 months or longer showed better progression-free outcomes compared to shorter treatment durations, indicating potential benefits of extended therapy duration.
87 citations
,
December 2016 in “British journal of dermatology/British journal of dermatology, Supplement” This study describes and characterizes four cases of alopecia areata induced by immune checkpoint inhibitor therapy in cancer patients, highlighting the importance of recognizing and managing these hair-related adverse events.
12 citations
,
March 2021 in “JAAD Case Reports” This study reported that immunotherapy in cancer patients can lead to skin-related immune adverse events, such as rashes, pruritus, and vitiligo, affecting a substantial proportion of patients.